Overview

  • Product name
    Anti-TGF beta Receptor I antibody
    See all TGF beta Receptor I primary antibodies
  • Description
    Rabbit polyclonal to TGF beta Receptor I
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rat, Cow
  • Immunogen

    Recombinant protein fragment, corresponding to a region within amino acids 1-268 of Human TGF beta Receptor I (Uniprot ID P36897)

  • Positive control
    • A431, HeLa and HepG2 cell lysates; HeLa cells; Human CL1-5 xenograft tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab155258 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 56 kDa.
IHC-P 1/100 - 1/1000.
ICC/IF 1/100 - 1/1000.

Target

  • Function
    On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.
  • Tissue specificity
    Found in all tissues examined, most abundant in placenta and least abundant in brain and heart.
  • Involvement in disease
    Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
    Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
    Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance.
  • Sequence similarities
    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
    Contains 1 GS domain.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AAT 5 antibody
    • AAT5 antibody
    • Activin A receptor type II like kinase 53kDa antibody
    • Activin A receptor type II like kinase, 53kD antibody
    • Activin A receptor type II like protein kinase of 53kD antibody
    • activin A receptor type II-like kinase, 53kDa antibody
    • activin A receptor type II-like protein kinase of 53kD antibody
    • Activin receptor like kinase 5 antibody
    • Activin receptor-like kinase 5 antibody
    • ACVRLK 4 antibody
    • ACVRLK4 antibody
    • ALK 5 antibody
    • ALK-5 antibody
    • ALK5 antibody
    • LDS1A antibody
    • LDS2A antibody
    • MSSE antibody
    • Serine/threonine protein kinase receptor R4 antibody
    • Serine/threonine-protein kinase receptor R4 antibody
    • SKR 4 antibody
    • SKR4 antibody
    • TbetaR I antibody
    • TbetaR-I antibody
    • TGF beta receptor type 1 antibody
    • TGF beta receptor type I antibody
    • TGF beta type I receptor antibody
    • TGF-beta receptor type I antibody
    • TGF-beta receptor type-1 antibody
    • TGF-beta type I receptor antibody
    • TGFBR 1 antibody
    • TGFBR1 antibody
    • TGFBR1 protein antibody
    • TGFR 1 antibody
    • TGFR-1 antibody
    • TGFR1 antibody
    • TGFR1_HUMAN antibody
    • Transforming growth factor beta receptor 1 antibody
    • Transforming growth factor beta receptor I (activin A receptor type II like kinase, 53kD) antibody
    • Transforming growth factor beta receptor I antibody
    • transforming growth factor, beta receptor 1 antibody
    • transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD) antibody
    • Transforming growth factor-beta receptor type I antibody
    see all

Images

  • All lanes : Anti-TGF beta Receptor I antibody (ab155258) at 1/1000 dilution

    Lane 1 : A431 whole cell lysate
    Lane 2 : HeLa whole cell lysate
    Lane 3 : HepG2 whole cell lysate

    Lysates/proteins at 30 µg per lane.

    Predicted band size: 56 kDa



    7.5% SDS PAGE
  • Immunofluorescence analysis of methanol-fixed HeLa cells, labeling TGF beta Receptor I using ab155258 at a 1/500 dilution. The image in the lower panel was costained with Hoechst 33342.
  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human CL1-5 xenograft tissue, labeling TGF beta Receptor I using ab155258 at a 1/500 dilution.

References

This product has been referenced in:
  • Zhuang R  et al. CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-ß-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 8:94759-94768 (2017). Read more (PubMed: 29212264) »

See 1 Publication for this product

Customer reviews and Q&As

56kDa is predicted band size based on the molecular weight calculations. http://www.uniprot.org/uniprot/P36897. The observed band size should be different because 33 amino acids correspond to signal peptide that gets chopped off when proteins are produ...

Read More

Thank you very much for getting back to me and for confirming the construct details.

If you have a chance, it would be still worth running a good positive control (cytospin preparation from A549 cells or tissue section from placenta) which en...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up